MD PARBEJ ALLAM

Dr. MD PARBEJ ALLAM

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Medical Sciences
Verified
Journal Article
Open access
PDF file
ZRZishan Rahman
Zishan Rahman
ANAhsan Nazim
Ahsan Nazim
PMPalvi Mroke
Palvi Mroke
KAKhansa Ali
Khansa Ali
MAMD PARBEJ ALLAM
MD PARBEJ ALLAM
EMErnesto Calderon Martinez
Ernesto Calderon Martinez
Sleep apnea-hypopnea syndrome (SAHS) is a respiratory disorder characterized by cessation of breathing during sleep, resulting in daytime somnolence and various comorbidities. SAHS encompasses obstructive sleep apnea (OSA), caused by upper airway obstruction, and central sleep apnea (CSA), resulting from lack of brainstem signaling for respiration. Continuous positive airway pressure (CPAP) therapy is the gold standard treatment for SAHS, reducing apnea and hypopnea episodes by providing continuous airflow. CPAP enhances sleep quality and improves overall health by reducing the risk of comorbidities such as hypertension, type 2 diabetes mellitus, cardiovascular disease and stroke. CPAP nonadherence leads to health deterioration and occurs due to mask discomfort, unsupportive partners, upper respiratory dryness, and claustrophobia. Technological advancements such as auto-titrating positive airway pressure (APAP) systems, smart fit mask interface systems, and telemonitoring devices offer patients greater comfort and enhance adherence. Future research should focus on new technological developments, such as artificial intelligence, which may detect treatment failure and alert providers to intervene accordingly.

4 August 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MAMD PARBEJ ALLAM
MD PARBEJ ALLAM
SSSmriti Shakya
Smriti Shakya
VYVijay Mbbs Yadav
Vijay Mbbs Yadav
SKShradha Mbbs Kc
Shradha Mbbs Kc
HSHari Mbbs Sedai
Hari Mbbs Sedai
AMArun Kumar Mbbs Mahato
Arun Kumar Mbbs Mahato
Introduction and importance: Aluminum phosphide (ALP) is a commonly used suicidal agent in an agrarian country like Nepal. The unmasking of the Brugada pattern in the electrocardiogram (ECG) associated with ALP poisoning is a rare phenomenon, and studies pertaining to it are scarce in the medical literature. Case presentation: An 18-year-old female presented to the emergency department with multiple episodes of vomiting, headache, blurring of vision, and abdominal pain after 4 h of consumption of ALP with suicidal intent. A 12-lead ECG revealed a coved ST-segment elevation and T-wave inversion in leads V1–V3 with right bundle branch block suggestive of a type 1 Brugada pattern. Her past medical and family history was not significant. The patient made an uneventful recovery with the required supportive treatments. Clinical discussion: Cardiac arrhythmias are the major cause of death in ALP poisoning. Unmasking of the Brugada ECG pattern is a rare but potentially fatal complication implicated in various pharmacological toxicities, including tricyclic antidepressants, cocaine, procainamide, disopyramide, flecainide, and rarely with ALP. Conclusions: ALP poisoning can unmask the Brugada ECG pattern, which can lead to ventricular fibrillation and/or sudden cardiac death.

12 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
GMGovind Singh Mann
Govind Singh Mann
SKSanam Wasim Khan
Sanam Wasim Khan
TMThrinatha Movva
Thrinatha Movva
AMAbdalla Malik
Abdalla Malik
LALeeda Ahmadi
Leeda Ahmadi
Binay Kumar PanjiyarBinay Kumar Panjiyar
Binay Kumar Panjiyar
Aim: Deep brain stimulation (DBS) involves implanting electrodes in specific brain areas. High-frequency Stimulation (HFS) and low-frequency Stimulation (LFS) target motor and non-motor symptoms differently. DBS is crucial in Parkinson's disease treatment for managing medication-resistant symptoms and improving quality of life. This review aims to evaluate the differential impact of high-frequency and low-frequency deep brain stimulation (DBS) on motor symptoms in Parkinson's disease (PD) patients. This systematic review adheres to PRISMA guidelines and focuses on clinical studies involving human subjects. Methods: Systematic search in electronic databases (PubMed, Google Scholar, Science Direct, Cochrane Collaboration Database of Randomized Trials) was performed to identify randomized controlled trials (RCTs) up to 13th July 2024. Results: Among 126 pooled patients from 8 RCTs, it was found that LFS significantly improved gait stability, swallowing, and verbal fluency with minimal adverse effects. Conversely, HFS was effective in reducing rigidity and tremor but was associated with potential side effects such as gait and speech impairment. Conclusion: The review highlights the nuanced effects of STN-DBS frequencies in Parkinson's treatment, suggesting high-frequency improves rigidity and tremor but may cause side effects, while low-frequency enhances gait stability and speech, necessitating further research for optimized, patient-specific therapies.


23 January 2026 in Clinical Case Reports
Verified
Journal Article
Open access
BKBirat Kadel
Birat Kadel
APAshok Paudel
Ashok Paudel
MAMD PARBEJ ALLAM
MD PARBEJ ALLAM
STSumin Thapa
Sumin Thapa
SDSujan Dhital
Sujan Dhital
Severe supravalvular aortic stenosis in a young patient is a rare but critical condition requiring timely diagnosis and intervention. We report a 15‐year‐old girl presenting with exertional dyspnea, chest pain, and palpitations. Echocardiography and multidetector computed tomography (MDCT) confirmed severe supravalvular aortic stenosis, myxomatous mitral valve with moderate to severe mitral regurgitation, and reduced ejection fraction. A double patch aortoplasty was performed with a successful outcome. This case underscores the importance of early diagnosis and tailored surgical intervention along with continued monitoring during follow up visits in managing complex congenital heart disease (CHD) diagnosed at an early age.

11 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
FAFnu Asifa
Fnu Asifa
AUahsan ullah
ahsan ullah
MAMD PARBEJ ALLAM
MD PARBEJ ALLAM
GMGovind Singh Mann
Govind Singh Mann
SJShivangi Jha
Shivangi Jha
BPBinay Kumar Panjiyar
Binay Kumar Panjiyar
Background: Cardiovascular comparisons between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium-glucose co-transporter-2 (SGLT-2) inhibitors in type 2 diabetes(T2D) remain an area of interest. Thus, the purpose of this meta-analysis is to compare the impact of these two drug classes on major CV outcomes, such as heart failure hospitalization(HHF), major adverse cardiovascular events (MACE), CV mortality, myocardial infarction, stroke, and all-cause mortality, with an emphasis on heart failure hospitalizations. Methods: PubMed (including MEDLINE), Google Scholar, Cochrane Central Library, PLOSONE, and Science Direct databases were searched for studies that compared GLP-1 RAs and SGLT-2 inhibitors in patients with type 2 diabetes. Six cohort studies were selected for the analysis. Odds ratios (OR) with 95% CI were calculated and a random-effects model was used to estimate the hazard ratios (HR) of the studies. The quality of the studies was evaluated using the Newcastle-Ottawa Scale (NOS), and publication bias was assessed using funnel plots and Egger’s test. Results: Pooled analysis demonstrated a significant reduction in heart failure hospitalizations with SGLT-2 inhibitors compared to GLP-1 RAs (HR: 0.78 [0.62–0.98], I² = 87%, p < 0.01). Cardiovascular mortality was also significantly reduced by SGLT-2 inhibitors (HR: 0.74 [0.31–1.67], I² = 87%, p < 0.01), and a modest reduction was observed for all-cause mortality (HR: 0.85 [0.44–1.64], I² = 17%, p = 0.27). While SGLT-2 inhibitors appeared to slightly reduce the risk of myocardial infarction (HR: 0.83 [0.74–0.92], I² = 0%, p = 0.85), no significant difference was observed for MACE (HR: 0.91 [0.82–1.01], I² = 0%, p = 0.70) or stroke (HR: 0.88 [0.77–1.00], I² = 0%, p = 0.85). Conclusions: Compared to GLP-1 receptor agonists, SGLT-2 inhibitors were more effective in lowering heart failure hospitalizations and cardiovascular mortality in patients with type 2 diabetes. It was also found that all-cause mortality and myocardial infarction were moderately reduced using oral agents. However, the differences were not significant for MACE or stroke. These results imply that SGLT-2 inhibitors may potentially provide better cardiovascular benefits, especially with respect to heart failure and cardiovascular mortality, than GLP-1 RA. Further research should be conducted to determine the effects of the long-term use of these therapies on stroke and other cardiovascular events.